| Liu, Hong |
| Recruiting | 4 | 1428 | RoW | Indomethacin SR, YINDUOMEIXIN, Placebos, sham | Peking Union Medical College Hospital | Acute Pancreatitis, Complication, Mortality Rate, Organ Failure, Multiple | 06/28 | 06/30 | | |
NCT04134026: Evaluate the Efficacy and Safety of HIF-PHI for the Treatment of Anemia and Risks of Cardiovascular and Cerebrovascular Events in ESRD Newly Initiated Dialysis Patients |
|
|
| Not yet recruiting | 4 | 400 | RoW | HIF-PHI, Epoetin Alfa, Epogen | Second Xiangya Hospital of Central South University | Anemia in Incident Dialysis Patients | 10/23 | 10/24 | | |
NCT06142552: Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein |
|
|
| Recruiting | 3 | 120 | RoW | FRSW117, Recombinant human coagulation factor Ⅷ-Fc fusion protein for injection | Jiangsu Gensciences lnc. | Severe Hemophilia A | 01/26 | 09/26 | | |
TAPIS, NCT06316570: Ticagrelor With Aspirin Dual Antiplatelet Therapy Combined With Intravenous Thrombolysis for Ischemic Stroke |
|
|
| Recruiting | 3 | 1380 | RoW | Early Dual Antiplatelet Therapy, Ticagrelor and Aspirin, Placebo, Placebo of Ticagrelor and Aspirin | Beijing Tiantan Hospital | Ischemic Stroke, Acute | 12/25 | 12/26 | | |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT05173272: Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical Cancer |
|
|
| Recruiting | 3 | 286 | RoW | Neoadjuvant Therapy, Neoadjuvant chemotherapy combined with Serplulimab, CCRT, chemoradiation, Brachytherapy | Sichuan Cancer Hospital and Research Institute | Cervical Cancer | 12/27 | 12/28 | | |
NCT04736186: Prevention and Treatment of Pyrrolitinib-associated Diarrhea |
|
|
| Recruiting | 2/3 | 470 | RoW | Loperamide, Loperamide and golden bifid, Loperamide and montmorillonite powder | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 10/22 | 04/23 | | |
NCT04836520: SHR6390 Combined With Anastrozole for Preoperative Treatment of Breast Cancer. |
|
|
| Completed | 2 | 20 | RoW | SHR6390+anatrozole | Tianjin Medical University Cancer Institute and Hospital, Jiangsu HengRui Medicine Co., Ltd. | Breast Cancer | 02/23 | 03/23 | | |
NCT05641506: A Chinese Patent Medicine Yangzhengxiaoji Capsule to Improve the Nausea of Niraparib in the Maintenance Treatment in Ovarian Cancer |
|
|
| Not yet recruiting | 2 | 50 | RoW | Yangzheng Xiaoji, Niraparib | Sichuan Cancer Hospital and Research Institute | Ovarian Cancer | 10/23 | 05/25 | | |
| Recruiting | 2 | 86 | RoW | Penpulimab, Anlotinib | Sichuan Cancer Hospital and Research Institute | Gynecological Cancer | 12/24 | 12/25 | | |
NCT04562870 / 2020-003809-60: A Study to Evaluate Single Agent Selinexor Versus Physician's Choice in Participants with Previously Treated Myelofibrosis |
|
|
| Active, not recruiting | 2 | 112 | Europe, US, RoW | Selinexor, Physician's Choice Treatment | Karyopharm Therapeutics Inc | Myelofibrosis | 01/25 | 01/25 | | |
|
|
| Active, not recruiting | 1/2 | 121 | RoW | CAR-BCMA T Cells | CARsgen Therapeutics Co., Ltd., Beijing Chao Yang Hospital, The First Affiliated Hospital of Soochow University, Xinhua Hospital, Shanghai Jiao Tong University School of Medicine, Tianjin Medical University General Hospital, First Affiliated Hospital of Zhejiang University, Beijing Hospital, Shanghai Tongji Hospital, Tongji University School of Medicine, First Affiliated Hospital of Wenzhou Medical University, Xiangya Hospital of Central South University, Peking University People's Hospital, Qilu Hospital of Shandong University, Sun Yat-sen University, First Affiliated Hospital, Sun Yat-Sen University | Multiple Myeloma | 12/24 | 12/25 | | |
| Recruiting | 1/2 | 430 | RoW | IBI363, IBI325, Lenvatinib | Hunan Province Tumor Hospital, Xiangya Hospital of Central South University | Advanced Solid Tumor | 12/26 | 09/28 | | |
NCT06756321: A Study of CAR T-Cells in Relapsed/Refractory Hematologic Malignancy |
|
|
| Recruiting | 1 | 9 | RoW | anti-CD19-CAR T-cells, or anti-CD30-CAR T-cells, or anti-CD20/CD30-CAR T-cells, Fludarabine, Cyclophosphamide | Affiliated Hospital of Nantong University, Shanghai First Song Biotechnology Co., LTD | Relapsed/refractory Lymphoma, Relapsed/Refractory Leukemia | 03/25 | 03/26 | | |
NCT04993794: Additive Anti-inflammatory Action for Critically Ill Patients With Cardiovascular Surgery (Xuebijing) IV |
|
|
| Recruiting | N/A | 200 | RoW | XueBiJing Injection, Normal saline | Nanjing Medical University | Cardiovascular Disease, Aortic Dissection, Coronary Artery Disease, Valve Heart Disease, Congenital Heart Disease, Critical Illness | 12/22 | 12/22 | | |
PANDA V, NCT04444349: Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery |
|
|
| Recruiting | N/A | 500 | RoW | Coenzyme Q10, ubiquinone, Standard Medical Therapy | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University | Cardiovascular Disease | 12/25 | 12/25 | | |
NTU-CML-001, NCT05152537: FLOR3 Gene Polymorphism in Predicting Outcomes of Tyrosine Kinase Inhibitor（TKI）Stopping in Chronic Myeloid Leukemia |
|
|
| Recruiting | N/A | 15 | RoW | | Affiliated Hospital of Nantong University | Folate, CML, Treatment-free Remission | 06/23 | 12/23 | | |
NCT04216823: Perfusion Index as an Objective Measure for Supraclavicular Brachial Plexus Block in Pediatric Patients |
|
|
| Completed | N/A | 104 | RoW | perfusion index | Tongji Hospital | Supraclavicular Brachial Plexus Block | 06/23 | 06/23 | | |
NCT05686863: Remiazolam Combined With Esketamine in Painless Bidirectional Endoscopy in Children |
|
|
| Completed | N/A | 106 | RoW | Remimazolam, Rema, Esketamine, Esket, Propofol, Prop, remifentanil, remifen | Tongji Hospital | Drug Effect | 07/23 | 07/23 | | |
PANDA, NCT04699279: Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery ( III) |
|
|
| Recruiting | N/A | 300 | RoW | Rosuvastatin 10mg | Nanjing Medical University, Beijing Anzhen Hospital, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University, The Affiliated Hospital of Qingdao University Medical College | Acute Aortic Syndrome, Aortopathy | 12/24 | 12/24 | | |
NCT05487469: Thymosin α1 Use in Rheumatic Heart Disease Patients Undergoing Cardiac Surgery on Cardiopulmonary Bypass |
|
|
| Recruiting | N/A | 200 | RoW | Thymosin Alpha1, Blank Control | Nanjing Medical University | Rheumatic Heart Disease, Cardiopulmonary Bypass, Immunotherapy | 12/23 | 12/23 | | |
Panda II, NCT05339529: Protective Effect of Thymosin Α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA II) |
|
|
| Recruiting | N/A | 330 | RoW | Thymosin Alpha1, 28A-Glycine-28B-L-Arginine-28C-L-Glutamic Acid-28D-L-Alanine-28E-L-Proline-28F-L-Alanine-28G-L-Asparagine-, Blank control | Nanjing Medical University, Beijing Anzhen Hospital, Second Affiliated Hospital of Nanchang University, Qilu Hospital of Shandong University, The First Affiliated Hospital of Guangzhou Medical University, Northern Jiangsu People's Hospital, Guangdong Provincial People's Hospital, First Affiliated Hospital of Kunming Medical University, Nanjing First Hospital, Nanjing Medical University, Shanghai East Hospital,Tongji University School of Medicine, The Seventh Affiliated Hospital of Xinjiang Medical University, Teda International Cardiovascular Hospital, Tianjin, China, First Affiliated Hospital Bengbu Medical College, West China Hospital Affiliated with Sichuan University | Acute Aortic Syndrome, Aortic Dissection Type a | 12/25 | 12/25 | | |
NCT05782881: High Risk Population of Cardiovascular Disease in Hubei Province Screening and Intervention Program |
|
|
| Recruiting | N/A | 16000 | RoW | phone calls and encouraging patients' lifestyle change and medication adherence, Statin, Angiotensin-converting enzyme inhibitor, Angiotensin receptor neprilysin inhibitor, Glucagon-like peptide-1, Sodium-dependent glucose transporters 2 | Wuhan Union Hospital, China, Peking University First Hospital | Cardiovascular Diseases, Diabetes Mellitus, Type 2, Coronary Disease | 12/23 | 12/24 | | |
NCT05881655: Slow Myopia Progression With Different Irradiance Light |
|
|
| Recruiting | N/A | 75 | RoW | Airdoc Red Lighting Device, Repeated Red Light, Low Lever Laser Therapy, Low Intensity Light Therapy, Photobiomodulation Therapy, Seconee, 650nm Red Light, Special Spectacles to Control Myopia, Essilor® Stellest™ Lenses, H.A.L.T lens | Beijing Airdoc Technology Co., Ltd., Shanghai Children's Medical Center | Myopia, Progressive | 05/24 | 12/25 | | |
PANDA VI, NCT06195267: Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Recruiting | N/A | 500 | RoW | Sivelestat, Blank control | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital | Aortic Dissection, Systemic Inflammatory Response Syndrome, Cardiovascular Diseases (CVD) | 12/25 | 12/25 | | |
COSEFDIP, NCT05755659: Clinical on the Safety and Efficacy of Fosaprepitant Dimeglumine for Injection in the Prevention of CINV. |
|
|
| Recruiting | N/A | 3000 | RoW | Fosaprepitant Dimeglumine for Injection, ShanQi®️ | Xijing Hospital | Neoplasms | 10/24 | 12/24 | | |
PANDA, NCT06707350: Protective Effect of RIPC Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery (Panda VII) |
|
|
| Not yet recruiting | N/A | 500 | RoW | Remote ischemic preconditioning (RIPC), sham condition (control group) | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University | Cardiopulmonary Bypass, Cardiovascular Diseases, Inflammatory Response During Cardiac Surgery | 12/25 | 12/25 | | |
NCT04837222: A Study of Brentuximab Vedotin in Adults With CD30-positive Lymphoma |
|
|
| Active, not recruiting | N/A | 1000 | RoW | No Intervention | Takeda | Lymphoma | 06/26 | 06/26 | | |
NCT06723366: Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery |
|
|
| Not yet recruiting | N/A | 120 | RoW | Angong Niuhuang Pill (ANP), Control (Standard treatment) | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital, Capital Medicine University | Cardio-pulmonary Bypass, Cardiovascular Surgery, Cerebral Protection, Brain Injury | 12/25 | 12/25 | | |
PANDA, NCT06730802: Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting ( VIII) |
|
|
| Not yet recruiting | N/A | 400 | RoW | PCSK9 inhibitor, Statin | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University, Beijing Anzhen Hospital | Myocardial Ischaemic Syndrome, Coronary Heart Disease | 12/26 | 12/26 | | |
NCT01932411: Factors Affect Outcomes in Cardiovascular Surgery |
|
|
| Recruiting | N/A | 5000 | US | | University of California, Davis | Coronary Artery Disease, Valvular Diseases, Vascular Diseases | 02/25 | 07/25 | | |
| Recruiting | N/A | 2000 | RoW | Renal replacement therapy | Nanjing Medical University | Acute Kidney Injury, Cardiac Surgery | 12/25 | 12/25 | | |
NCT04398992: Additive Anti-inflammatory Action for Aortopathy & Arteriopathy |
|
|
| Enrolling by invitation | N/A | 10000 | RoW | observation | Nanjing Medical University, Beijing Anzhen Hospital | Acute Aortic Syndrome | 12/40 | 12/40 | | |
| Recruiting | N/A | 500 | RoW | soluble ST2 | Nanjing Medical University | Cardiovascular Disease | 12/25 | 12/25 | | |
PANDA IV, NCT04444362: Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Enrolling by invitation | N/A | 500 | RoW | Intestinal Microbiota Transplant (IMT) Capsules | Nanjing Medical University, Beijing Anzhen Hospital, Shanghai East Hospital of Tongji University, West China Hospital, The First Affiliated Hospital of Guangzhou Medical University | Cardiovascular Disease, Cardiopulmonary Bypass | 12/25 | 12/25 | | |
PANDA, NCT06728605: Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery |
|
|
| Not yet recruiting | N/A | 400 | RoW | Enhanced External Counterpulsation (EECP), Sham Comparator | Nanjing Medical University, The First Affiliated Hospital with Nanjing Medical University | Coronary Heart Disease (CHD), Cardio-pulmonary Bypass, Congestive Heart Failure Chronic, Cardiogenic Shock Acute | 12/25 | 12/25 | | |
BEST-BAO, NCT05631847: Direct Endovascular Treatment Versus Bridging Treatment In Basilar Artery Occlusive Stroke |
|
|
| Recruiting | N/A | 336 | RoW | Endovascular treatment, Intravenous thrombolysis (Alteplase) | Sichuan Academy of Medical Sciences, Sichuan Provincial People's Hospital | Acute Ischemic Stroke, Basilar Artery Occlusion, Thrombosis, Alteplase, Endovascular Treatment | 01/27 | 05/27 | | |
| Recruiting | N/A | 10000 | RoW | NIS | Second Affiliated Hospital, School of Medicine, Zhejiang University | Psoriasis | 07/30 | 07/30 | | |
NCT05454397: A Study on the Status of Nutritional Risk Screening and Nutritional Therapy in Neurology Hospitalized Stroke Patients |
|
|
| Recruiting | N/A | 2000 | RoW | Observational study, no intervention | Nanfang Hospital of Southern Medical University, First Affiliated Hospital of Fujian Medical University, Yantai Yuhuangding Hospital, The First Hospital of Jilin University, Qilu Hospital of Shandong University, ZHEJIANG PROVINCE XIAOSHAN HOSPITAL, The First People's Hospital of Wenling, Ganzhou People's Hospital, Affiliated Hospital of Jining Medical hospital, Henan Provincial People's Hospital, Zhongda Hospital Southeast University, The Second Affiliated Hospital of Harbin Medical University, The First people's Hospital of Kunshan, The 2nd Affiliated Hospital of Wenzhou Medical University, THE FIRST PEOPLE'S HOSPITAL OF JIASHAN, The First Affiliated Hospital of Xi'an Jiaotong University Medical College, Fujian Province Zhangzhou Hospital, People's Hospital of Chongqing, Nanjing Zijin Hospital, Hangzhou Red Cross Hospital, Wenzhou Hospital of Chinese Medicine, Kaifeng Central Hospital, First Affiliated Hospital of Guangxi Medical University, Zhongshan Hospital of Xiamen University, Xi'an Encephalopathy of Traditional Chinese Medicine Hospital, 903 Hospital of the Chinese People's Liberation Army Joint Logistics and Security Forces, Xiangya Hospital of Central South University, Second Affiliated Hospital of Suzhou University, Tongji Hospital, The Affiliated Hospital o fQingdao University, The First Affiliated Hospital of Anhui Medical University, Yancheng Third People's Hospital, Linyi People's Hospital, Dongfang Hospital of Beijing University of Chinese Medicine, Affiliated Hospital of Qingdao University | Acute Stroke | 10/22 | 10/23 | | |
NCT04970264: A Multicenter, Open and Observational Real World Study on the Prognosis and Treatment in Young Women With Breast Cancer |
|
|
| Recruiting | N/A | 2000 | RoW | | Tianjin Medical University Cancer Institute and Hospital | Breast Cancer | 03/23 | 03/25 | | |
| Recruiting | N/A | 300 | RoW | ECMO | Nanjing Medical University | Cardiogenic Shock, Cardiac Arrest, Heart Failure, Acute Respiratory Failure, Acute Respiratory Distress Syndrome | 12/25 | 12/25 | | |
| Recruiting | N/A | 1000 | RoW | Intra Aortic Balloon Pump | Nanjing Medical University | Acute Coronary Syndrome, Cardiogenic Shock, Coronary Artery Disease, Heart Failure, Left Ventricular Dysfunction, Low Cardiac Output Syndrome, Post-cardiac Surgery | 12/25 | 12/25 | | |
| Yang, Nong |
NCT05055908: Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors |
|
|
| Recruiting | 3 | 12000 | RoW | Pemetrexed plus Pembrolizumab, Bevacizumab, Pembrolizumab, Pemetrexed | Hunan Province Tumor Hospital | Lung Cancer | 07/25 | 09/27 | | |
NCT05549037: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC |
|
|
| Recruiting | 3 | 210 | RoW | Pembrolizumab, Sintilimab, time-of-day of administration of immunochemotherapy | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
NCT05014464: ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Crizotinib, Alectinib, Brigatinib, Lorlatinib, Pemetrexed, immune checkpoint inhibitors, Carboplatin, Paclitaxel | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 06/26 | 08/27 | | |
ESSENTIAL, NCT05284539: Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer |
|
|
| Recruiting | 2 | 760 | RoW | Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab, Pemetrexed, Bevacizumab, Pembrolizumab, Atezolizumab | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 09/26 | 10/27 | | |
| Recruiting | 2 | 200 | RoW | BEBT-109 Capsule, KCBT-1083 | BeBetter Med Inc | Non-Small Cell Lung Cancer, EGFR Exon 20 Insertion Mutation | 12/25 | 06/26 | | |
NCT04951947: JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | JS201 combine with Lenvatinib | Hunan Province Tumor Hospital | Small-cell Lung Cancer | 12/24 | 06/25 | | |
TOGATHER, NCT04144608: Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC |
|
|
| Completed | 2 | 40 | RoW | Toripalimab, platinum-based chemotherapy | Yongchang Zhang | Advanced Non Small Cell Lung Cancer | 06/22 | 07/23 | | |
| Recruiting | 2 | 43 | RoW | Anlotinib and Docetaxel | Yongchang Zhang | Non-Squamous Non Small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT05001971: Anlotinib Plus Penpulimab for the Treatment of Sensitive Relapsed Small-Cell Lung Cancer |
|
|
| Recruiting | 2 | 73 | RoW | Anlotinib Plus Penpulimab, Anlotinib & Penpulimab | Hunan Cancer Hospital, Fuzhou Pulmonary Hospital of Fujian, Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Small Cell Lung Cancer | 06/23 | 12/23 | | |
NCT05584267: Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy |
|
|
| Recruiting | 2 | 140 | RoW | radiotherapy, Chemotherapy + immunotherapy | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 11/25 | 12/26 | | |
NCT05266846: Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK |
|
|
| Recruiting | 2 | 78 | RoW | Pembrolizumab injection, pemetrexed, Bevacizumab, CISPLATIN | Hunan Province Tumor Hospital | ALK Gene Mutation, Lung Adenocarcinoma, Immunotherapy | 11/26 | 02/27 | | |
NCT02098954: Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers |
|
|
| Recruiting | 2 | 40 | RoW | Gemcitabine platinum combined with erlotinib, Gemzar, Tarceva | Hunan Province Tumor Hospital | Carcinoma, Non-Small Cell Lung, EGFR Gene Mutation | 12/24 | 12/25 | | |
| Recruiting | 2 | 71 | RoW | SHR-1701 Combined With Fluazopalil | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT04144569: PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC |
|
|
| Recruiting | 2 | 30 | RoW | PD-1 Combined With Pyrotinib | Yongchang Zhang | HER2 Insertion Mutation Positive Advanced NSCLC | 12/24 | 12/24 | | |
WUKONG-32, NCT06348927: Sunvozertinib Plus Anlotinib as 1L Treatment in EGFR-Sensitive Mutations Combined With Co-Mutations Advanced NSCLC |
|
|
| Recruiting | 2 | 52 | RoW | sunvozertinib in combination with Anlotinib | Hunan Province Tumor Hospital | Non-Small Cell Lung Cancer | 10/25 | 04/27 | | |
NCT05411679: EP0057 in Combination With Olaparib in Relapsed Advanced Gastric Cancer and Small Cell Lung Cancer |
|
|
| Withdrawn | 2 | 115 | RoW | EP0057, Olaparib tablets | Ellipses Pharma | Gastric Cancer, Small-cell Lung Cancer | 08/24 | 12/24 | | |
| Not yet recruiting | 2 | 172 | RoW | Crisugabalin, Pregabalin | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Neuropathic Pain | 11/26 | 12/26 | | |
SKB264-II-04, NCT05816252: A Study of SKB264 for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 498 | Europe, RoW | SKB264, MK-2870, Pembrolizumab, MK-3475, Carboplatin, Carboplatin for injection, Osimertinib, Osimertinib Mesylate | Klus Pharma Inc., Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Non-small Cell Lung Cancer | 12/25 | 10/26 | | |
| Recruiting | 1/2 | 280 | RoW | SAF-189s, foritinib succinate | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Advanced Cancer, Advanced Solid Tumor, Lung Cancer, Nonsmall Cell | 12/22 | 03/26 | | |
NCT05329298: A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors |
|
|
| Recruiting | 1/2 | 90 | RoW | BPI-361175 | Betta Pharmaceuticals Co., Ltd. | Non-small Cell Lung Cancer | 06/23 | 12/23 | | |
NCT04993391: AP-L1898 Capsule in Patients With Non-small Cell Lung Cancer |
|
|
| Recruiting | 1/2 | 156 | RoW | JS111(AP-L1898 Capsules) | Suzhou Junjing BioSciences Co., Ltd. | Lung Cancer | 06/24 | 08/24 | | |
NCT06109558: The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC |
|
|
| Recruiting | 1/2 | 120 | RoW | LMV-12(HE003), Osimertinib | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer, RET Gene Mutation, MET Amplification, EGF-R Positive Non-Small Cell Lung Cancer | 12/26 | 07/27 | | |
| Recruiting | 1/2 | 430 | RoW | IBI363, IBI325, Lenvatinib | Hunan Province Tumor Hospital, Xiangya Hospital of Central South University | Advanced Solid Tumor | 12/26 | 09/28 | | |
| Recruiting | 1/2 | 500 | Europe, Canada, Japan, US, RoW | Oral repotrectinib (TPX-0005), repotrectinib | Turning Point Therapeutics, Inc., Zai Lab (Shanghai) Co., Ltd. | Locally Advanced Solid Tumors, Metastatic Solid Tumors | 02/28 | 02/28 | | |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
NCT04825392: A Phase Ib Study of HX008 in Patients With Advanced Solid Tumors |
|
|
| Recruiting | 1 | 30 | RoW | HX008 | Taizhou Hanzhong biomedical co. LTD | Advanced Solid Tumor | 05/21 | 12/21 | | |
NCT04675060: Effect of High-fat Meal on the Pharmacokinetics of TQ-B3139 Capsules |
|
|
| Recruiting | 1 | 12 | RoW | TQ-B3139 capsules | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Advanced Solid Tumors | 03/22 | 03/22 | | |
NCT05337267: Phase I Study of Sintilimab in Healthy Chinese Male Subjects |
|
|
| Completed | 1 | 117 | RoW | sintilimab (after the change), sintilimab (before the change) | Innovent Biologics (Suzhou) Co. Ltd. | Healthy Male Subjects | 05/23 | 07/23 | | |
NCT05559242: Pharmacokinetic Study of Anlotinib Hydrochloride Capsules in Healthy Subjects and Liver Dysfunction Patients |
|
|
| Not yet recruiting | 1 | 30 | RoW | Anlotinib Hydrochloride Capsule | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Liver Dysfunction | 06/23 | 07/23 | | |
NCT04890587: A Phase I Study of AL8326 in Advanced Solid Tumor |
|
|
| Recruiting | 1 | 40 | RoW | AL8326 tablets, AL8326 | Advenchen Laboratories Nanjing Ltd. | Advanced Solid Tumors | 12/23 | 12/23 | | |
NCT05673538: TT-00973-MS Tablets in Patients With Advanced Solid Tumors |
|
|
| Not yet recruiting | 1 | 40 | RoW | TT-00973-MS tablets treatment | TransThera Sciences (Nanjing), Inc. | Advanced Solid Tumor | 12/24 | 12/25 | | |
NCT06183762: A Real-World Study of Treatment Patterns and Effectiveness in MET Mutation-Positive Advanced Lung Cancer |
|
|
| Recruiting | N/A | 200 | RoW | No treatment is included in this protocol. | Hunan Province Tumor Hospital | Advanced Lung Cancer | 12/24 | 06/25 | | |
NCT05059951: Chemotherapy With or Without Immune Checkpoint Inhibitors for Lung Cancer |
|
|
| Recruiting | N/A | 15000 | RoW | Immune checkpoint inhibitor, Chemotherapy | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 09/26 | 03/28 | | |
NCT03647111: Real World Study of First Line Crizotinib for ALK Rearranged Non-squamous Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 120 | RoW | Crizotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
NCT03646994: Real World Study on First Line Crizotinib in ROS1 Rearranged Advanced Non-squamous Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 40 | RoW | Crizotinib | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
NCT03647098: Analysis of Survival Status of KRAS Mutation Advanced Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 1500 | RoW | Chemotherapy., pemetrexed | Hunan Province Tumor Hospital | KRAS G12C, Non-small Cell Lung Cancer, KRAS G12D, KRAS G12V, KRAS G12R, KRAS G12Y, KRAS G13N | 12/26 | 12/28 | | |
NCT04777175: A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 186 | RoW | immunity therapy | Yongchang Zhang, Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 01/25 | 01/25 | | |
NCT03647592: Real World Study on Erlotinib/Gefitinib Combined With Bevacizumab in Advanced Non-aquamous Non-small Cell Lung Cancer |
|
|
| Recruiting | N/A | 30 | RoW | Erlotinib/Gefitinib combined with Bevacizumab, treatment of A+T | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 08/24 | 12/25 | | |
NCT06073938: Compassionate Use Study of NHWD-870 in Patients With Advanced Solid Tumors or Lymphomas Carrying NUT Rearrangement |
|
|
| Recruiting | N/A | 30 | RoW | NHWD-870 | Hunan Province Tumor Hospital | Advanced Solid Tumors or Lymphomas | 12/24 | 06/25 | | |
NCT05991206: A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC |
|
|
| Recruiting | N/A | 200 | RoW | | Hunan Province Tumor Hospital | NSCLC | 12/25 | 08/26 | | |
| chen, xiang |
nAMD, NCT05461339: TAB014 Compared to Lucentis® in Patients with Neovascular Age-related Macular Degeneration |
|
|
| Active, not recruiting | 3 | 488 | RoW | TAB014 Monoclonal Antibody Injection, TAB014, Ranibizumab Injection [Lucentis], Lucentis | TOT Biopharm Co., Ltd., Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd. | Neovascular Age-related Macular Degeneration | 09/24 | 02/25 | | |
NCT05181137 / 2021-001940-86: A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis |
|
|
| Recruiting | 3 | 368 | Europe, US, RoW | SHR0302, Placebo | Reistone Biopharma Company Limited, Reistone Biopharma Company Limited | Ulcerative Colitis | 10/24 | 03/25 | | |
| Recruiting | 1/2 | 430 | RoW | IBI363, IBI325, Lenvatinib | Hunan Province Tumor Hospital, Xiangya Hospital of Central South University | Advanced Solid Tumor | 12/26 | 09/28 | | |
NCT06024265: The Safety and Tolerability Study With ER2001 Intravenous Injection in Adults With Early Manifest Huntington's Disease |
|
|
| Recruiting | 1 | 15 | RoW | ER2001 injection, ER2001 intravenous injection solution | ExoRNA Bioscience | Huntington Disease | 10/24 | 12/24 | | |
NCT06365502: Preventive Drug-coated Balloon Angioplasty in Vulnerable Atherosclerotic Plaque (RESTORE Trial) |
|
|
| Recruiting | N/A | 1860 | RoW | Drug-coated balloon, Guideline-directed medical treatment | Harbin Medical University, Shanghai Shenqi Medical Technology Co., Ltd | Acute Coronary Syndrome (ACS) | 12/27 | 12/30 | | |
NCT06802848: Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real) |
|
|
| Not yet recruiting | N/A | 1000 | RoW | Xeligekimab injection | Chongqing Genrix Biopharmaceutical Co., Ltd, Xiangya Hospital of Central South University | Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis, Palmoplantar Psoriasis, Genital Psoriasis | 03/26 | 12/26 | | |
| Zhang, Yongchang |
NCT05055908: Efficacy and Biomarker Development for Lung Cancer Treated With Immune Checkpoint Inhibitors |
|
|
| Recruiting | 3 | 12000 | RoW | Pemetrexed plus Pembrolizumab, Bevacizumab, Pembrolizumab, Pemetrexed | Hunan Province Tumor Hospital | Lung Cancer | 07/25 | 09/27 | | |
NCT05549037: Effect of Time-of-Day (ToD) for Immunochemotherapy on PFS in NSCLC |
|
|
| Recruiting | 3 | 210 | RoW | Pembrolizumab, Sintilimab, time-of-day of administration of immunochemotherapy | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 12/24 | 12/25 | | |
SUNRAY-01, NCT06119581: A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer |
|
|
| Recruiting | 3 | 1016 | Europe, Canada, Japan, US, RoW | LY3537982, Olomorasib, Pembrolizumab, Placebo, Cisplatin, Carboplatin, Pemetrexed | Eli Lilly and Company, Loxo Oncology, Inc. | Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis | 10/26 | 10/29 | | |
| Recruiting | 2/3 | 1200 | RoW | Anlotinib plus the same Immune Checkpoint Inhibitors., Pembrolizumab, Sintilimab etc. have been used in the previous treatment., Anlotinib plus the new Immune Checkpoint Inhibitors., Pembrolizumab, Sintilimab etc. have not been used in the previous treatment., Anlotinib, Anlotinib monotherapy. | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 03/28 | 03/29 | | |
NCT05014464: ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 90 | RoW | Crizotinib, Alectinib, Brigatinib, Lorlatinib, Pemetrexed, immune checkpoint inhibitors, Carboplatin, Paclitaxel | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 06/26 | 08/27 | | |
ESSENTIAL, NCT05284539: Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer |
|
|
| Recruiting | 2 | 760 | RoW | Pemetrexed, Cisplatin, Bevacizumab Plus Pembrolizumab, Pemetrexed, Bevacizumab, Pembrolizumab, Atezolizumab | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 09/26 | 10/27 | | |
NCT04951947: JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | JS201 combine with Lenvatinib | Hunan Province Tumor Hospital | Small-cell Lung Cancer | 12/24 | 06/25 | | |
TOGATHER, NCT04144608: Toripalimab Combined With Double Platinum-based Chemotherapy for Initially Unresectable NSCLC |
|
|
| Completed | 2 | 40 | RoW | Toripalimab, platinum-based chemotherapy | Yongchang Zhang | Advanced Non Small Cell Lung Cancer | 06/22 | 07/23 | | |
PIKACHU, NCT04322890: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation |
|
|
| Recruiting | 2 | 6000 | RoW | Osimertinib, Erlotinib, Gefitinib, Furmonertinib, Almonertinib etc., Alectinib 150 MG, Lorlatinib, Alectinib, Brigatinib, Ceritinib etc., Crizotinib 250 MG, Entrectinib, Savolitinib, Crizotinib., Crizotinib, Chemotherapy, Pemetrexed, Cisplatin, Pralsetinib etc. | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer, EGFR Gene Mutation, ALK Gene Mutation, ROS1 Gene Mutation, MET Gene Mutation | 12/26 | 12/27 | | |
| Recruiting | 2 | 43 | RoW | Anlotinib and Docetaxel | Yongchang Zhang | Non-Squamous Non Small Cell Lung Cancer | 12/24 | 06/25 | | |
NCT04322578: Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC |
|
|
| Recruiting | 2 | 120 | RoW | Crizotinib, Savolitinib, Pemetrexed, immune checkpoint inhibitors, Carboplatin, Bevacizumab | Hunan Province Tumor Hospital | Non-small Cell Lung Cancer | 03/25 | 03/26 | | |
NCT05584267: Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision Radiotherapy |
|
|
| Recruiting | 2 | 140 | RoW | radiotherapy, Chemotherapy + immunotherapy | Hunan Province Tumor Hospital | Non Small Cell Lung Cancer | 11/25 | 12/26 | | |
